Inflammatory links between obesity and metabolic disease

Carey N. Lumeng¹,² and Alan R. Saltiel²,³,⁴

¹Department of Pediatrics and Communicable Diseases, ²Department of Molecular and Integrative Physiology, and ³Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA. ⁴Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA.

The obesity epidemic has forced us to evaluate the role of inflammation in the health complications of obesity. This has led to a convergence of the fields of immunology and nutrient physiology and the understanding that they are inextricably linked. The reframing of obesity as an inflammatory condition has had a wide impact on our conceptualization of obesity-associated diseases. In this Review, we highlight the cellular and molecular mechanisms at play in the generation of obesity-induced inflammation. We also emphasize how defining the immune regulation in metabolic tissues has broadened the understanding of the diversity of inflammatory responses.

Introduction
The burden of obesity on health extends across multiple organ systems and diseases. While its impact on tissues involved in nutrient regulation is manifest in the development of insulin resistance and type 2 diabetes, there are also unexpected connections between obesity and the risk of cancer and pulmonary diseases. Over the past decade, the search for a potential unifying mechanism behind the pathogenesis of obesity-associated diseases has revealed a close relationship between nutrient excess and derangements in the cellular and molecular mediators of immunity and inflammation. This has given birth to the concept of “metainflammation” (1) to describe the chronic low-grade inflammatory response to obesity. We present here a broad overview of the links between obesity and immune responses with a focus on metabolic disease and argue that the intersection between the pathways that control nutrient metabolism and inflammatory responses may be broadly applicable to our understanding of inflammation and the immune system.

The nature of obesity-induced inflammation
Inflammation is a coordinated response to harmful stimuli, with the goal of returning the system back to a normal baseline. The inflammatory response triggered by obesity involves many components of the classical inflammatory response to pathogens and includes systemic increases in circulating inflammatory cytokines and acute phase proteins (e.g., C-reactive protein), recruitment of leukocytes to inflamed tissues, activation of tissue leukocytes, and generation of reparative tissue responses (e.g., fibrosis; ref. 2). However, the nature of obesity-induced metainflammation is unique compared with other inflammatory paradigms (e.g., infection, autoimmune disease) in several key aspects. The chronic nature of obesity produces a tonic low-grade activation of the innate immune system that affects steady-state measures of metabolic homeostasis over time. Childhood obesity may place individuals at risk for lifelong metainflammation, since inflammatory markers are elevated in obese children as young as 3 years old (3). Superimposed on this chronic inflammation are recurrent acute episodes of nutrition-related immune activation induced by nutrient availability (fasting or high-fat meals) (4–6).

In addition, the multi-organ involvement of obesity-induced inflammation is unique and presents a challenge to researchers attempting to tease out disease mechanisms in complex metabolic systems (ref. 7 and Figure 1). It is clear that inflammation participates in the link between obesity and disease. Non-biased assessments of gene expression networks in adipose tissue identify a robust pattern of overexpressed inflammatory genes associated with obesity and metabolic disease and enriched for macrophage genes (8, 9). Multiple inflammatory inputs contribute to metabolic dysfunction, including increases in circulating cytokines (10), decreases in protective factors (e.g., adiponectin; ref. 11), and communication between inflammatory and metabolic cells. For example, direct and paracrine signals from M1 classically activated macrophages can impair insulin signaling and adipogenesis in adipocytes, while unstimulated or M2 alternatively activated macrophages fail to generate these effects (12). Similar effects on adipocyte inflammation and glucose transport are generated by signals from activated conventional T cells such as IFN-γ (13). In parallel, dysregulated macrophage-myocyte and macrophage-hepatocyte signaling can influence insulin sensitivity (14, 15).

While transient inflammatory states such as sepsis can have multi-organ effects, few other chronic inflammatory diseases are characterized by the features of pancreatic, liver, adipose, heart, brain, and muscle inflammation as is seen in obesity.

Immunity and the maintenance of metabolic homeostasis. In some cases, adaptive immune responses may be beneficial and help preserve metabolic homeostasis. All metabolic tissues contain resident populations of leukocytes present even in lean healthy animals, indicating that the immune system is poised to respond to nutrient-derived signals (16, 17). For example, the extent of adipose tissue macrophage (ATM) infiltration is dynamically altered with lipid flux in adipocytes in lean and obese states, and may serve to suppress lipolytic signals (4). ATMs are recruited to adipose tissue when chemokine or lipid release (lipolysis) is triggered and may function to promote lipid storage by suppressing lipolysis. These events could be classified as an inflammatory response, as it involves the acute recruitment of leukocytes to fat, but it lacks many of the cardinal signs of classic inflammation (dolor, rubor, calor, and tumor).

Reconciling these observations requires a more expansive view of what immunologic activation means beyond the classical proinflammatory paradigm. The diversity of ATM function sup-
ports this broad view, as does the observation that leukocytes adopt a wide range of activation states dependent upon the local stimuli (18). Upon stimulation by LPS and IFN-γ, macrophages assume a classical proinflammatory activation state (M1) that generates bactericidal or Th1 responses typically associated with obesity. In contrast, Th2 cytokines such as IL-4 and IL-13 generate an alternative macrophage activation state (M2) that promotes fibrotic responses and attenuation of classical NF-κB–dependent activation pathways. While ATMs likely assume a number of states along the M1/M2 spectrum depending on fat depot location and nutritional status (19, 20), increasing adiposity results in a shift in the inflammatory profile of ATMs as a whole from an M2 state to one in which classical M1 proinflammatory signals predominate (21–23).

Unique molecular links between the M1/M2 polarization axis and metabolism suggest that the homeostatic regulation of nutrient utilization and the immune system are coupled together. The M2 activation state is intrinsically linked to the activity of PPARδ and PPARγ, well-known regulators of lipid metabolism and mitochondrial activity (24). Ppard- and Pparg-knockout mice fail to generate an M2 activation state and are more susceptible to the M1-skewed inflammation that accompanies diet-induced obesity (DIO) in the liver and adipose tissue (17, 25, 26). Physiologic enhancement of the M2 pathways (e.g., eosinophil recruitment in parasitic infection) also appears to be capable of reducing metainflammation and improving insulin sensitivity (27).

In fat, the M2 state of resident ATMs is maintained by cytokine production (e.g., IL-4) from unique natural helper lymphocytes and eosinophils; the recruitment of these cells to fat is suppressed in the obese environment (27, 28). This demonstrates that maintaining metabolic homeostasis requires a balanced immune response and an integrated network of multiple cell types. Adipose tissue also contains potent tolerogenic CD4+ Tregs that are downregulated by obesity, a potential initiating event in metainflammation (13, 29). Likewise, there appear to be innate systems by which nutrient signals are utilized to self-limit inflammation. For example, the obesity-induced increase in expression of GPR120, an omega-3 fatty acid (FA) receptor on macrophages capable of attenuating M1 macrophage activation and increasing M2 gene expression, limits inflammation; it is possible that this mechanism might be exploited in future drug development (30).

**Figure 1**
Cellular mediators of inflammation and immunity in obesity. The multisystem effects of obesity are linked to an imbalance in homeostatic and proinflammatory immune responses. Obesity triggers inflammatory pathways in the brain and adipose tissue that dysregulate physiological responses that maintain insulin and leptin sensitivity. Over time, ectopic lipid accumulation in muscle, liver, and blood vessels activates tissue leukocytes, contributes to organ-specific disease, and exacerbates systemic insulin resistance. Cellular- and cytokine-mediated inflammation in pancreatic islets accelerates the progression toward diabetes. FFA, free FA; INS, insulin; KC, Kupffer cell; Tconv, conventional CD4+ T cells.

**Tissue specific proinflammatory changes with obesity**
The discovery of ATM activation with obesity sparked a wave of interest into how immune responses intersect with obesity (31, 32). We know now that the dynamic regulation of inflammatory cells with obesity is not limited to fat and that inflammatory and metabolic signals converge in a myriad of contexts. This provides new
opportunities to understand the pathogenesis of many organ-specific diseases associated with obesity (Figure 1).

**Pancreatic islets.** Relevant to type 2 diabetes is the demonstration that inflammation in pancreatic islets can reduce insulin secretion and trigger β cell apoptosis leading to decreased islet mass, critical events in the progression to diabetes (33, 34). The mediators of these effects are multifactorial and likely involve cytokines produced by β cells themselves (35). As in adipose tissue, macrophages accumulate in islets with DIO and may be a significant source of proinflammatory cytokines that block β cell function (36). This point is often ignored in studies that manipulate macrophages by Cre-mediated recombination or BM transplantation and may be an underappreciated mechanism for protection from diabetes in many animal models.

**Adipose tissue.** Adipose tissue insulin resistance and dysfunctional lipid storage in adipocytes are sentinel events in the progression toward metabolic dysregulation with obesity. Forced expansion of adipose tissue by transgenic overexpression of the adipokine adiponectin prevents metabolic disease despite massive obesity (37). Impaired lipogenic/adipogenic capacity is associated with increased visceral fat in obese adolescents (38), and smaller omental adipocytes is a feature of metabolically healthy obese adults (39). These findings support the model that lipid “spillover” from fat promotes metabolic disease by fostering ectopic lipid deposition. Since an estimated excess of 20–30 million macrophages accumulate with each kilogram of excess fat in humans, one could argue that increased adipose tissue mass is de facto a state of increased inflammatory mass (40).

Inputs into this inflammatory response include ER stress, adipose tissue hypoxia, and adipocyte death (41–43). Since changes in ATM number and gene expression profile occur coincident with the development of insulin resistance (41, 44), it is possible that ATMs are merely effectors of a coordinated inflammatory response that includes the accumulation of CD8+ T cells, Th1-polarized CD4+ T cells, and the loss of Tregs (29, 44). NK cells, NKT cells, and mast cells are also implicated in metainflammation (40, 45, 46). Overall, our challenge in understanding adipose tissue inflammation will be to identify the temporal and spatial interactions between leukocytes in fat in the context of inflammatory initiation as well as their resolution.

**Inflammation in liver and muscle.** Nonalcoholic fatty liver disease (NAFLD) is a strong risk factor for insulin resistance, nonalcoholic steatohepatitis, and dyslipidemia, independent of visceral adiposity (47). Many of the signaling pathways involved in both inflammation and metabolism are elevated in steatotic liver (e.g., JNK, TLR4, ER stress). Similar to the effects of obesity on adipose tissue, NAFLD is associated with an increase in M1/Th1 cytokines and quantitative increases in immune cells (48–50). In addition, modulation of PPARδ-dependent M2 polarization pathways protects mice from NAFLD (17, 26). These effects may be mediated via Kupffer cells resident in the liver, or by unique cell populations recruited to the liver with obesity (51). There is also evidence of increased inflammatory cytokine production and increased inflammation in skeletal muscle in obesity (52). Myocytes have the capacity to respond to inflammatory signals via pattern recognition receptors (PRRs) such as TLR4 with direct metabolic effects (53). Muscle inflammation may be linked to infiltrating macrophages that are induced in obese muscle and have properties of M1 activation (23, 54). This topic is complicated by the fact that leukocyte trafficking of monocytes and macrophages is intrinsically linked to muscle injury and repair (55), increasing the challenge of de-convoluting the acute and chronic inflammatory changes in muscle with DIO.

**Hypothalamic inflammation and obesity.** Human genome wide association studies have identified loci near or within numerous neuronal genes that affect BMI, suggesting that variation in the central control of metabolism plays a prominent role in genetic obesity risk (56). Lipid infusion and a high-fat diet (HFD) activate hypothalamic inflammatory signaling pathways, resulting in increased food intake and nutrient storage (57). With DIO, metabolites such as diacylglycerols and ceramides accumulate in the hypothalamus and induce leptin and insulin resistance in the CNS (58, 59). Part of this effect is mediated by saturated FAs, which activate neuronal JNK and NF-κB signaling pathways with direct effects on leptin and insulin signaling (60). Disruption of signaling through TLR4/MyD88, IKKβ/NF-κB, and ER stress pathways in neurons protects mice from DIO and its downstream metabolic effects (60–62).

The effects of brain inflammation on the metabolic function of peripheral tissues are broad. Independent of obesity, hypothalamic inflammation can impair insulin release from β cells, impair peripheral insulin action, and potentiate hypertension (63–65). Many of these effects are generated by signals from the sympathetic nervous system, which is also capable of inducing inflammatory changes in adipose tissue in response to neuronal injury (66). A future challenge is to understand how inflammatory signals in the brain generate responses that in some cases generate negative energy balance (anorexia), while in other cases generates positive energy balance (weight gain) (67).

The dynamic interplay between hypothalamic inflammation and obesity suggest additional targets for antiinflammatory therapies in obesity. A key extension of these observations is the potential that antiinflammatory pathways may counteract these CNS inflammatory events and improve leptin sensitivity. Recent evidence suggests that IL-6 and IL-10 are involved in the exercise-induced suppression of hyperphagia and suppress IKKβ/NF-κB and ER stress in the brain (68). The IKKβ/NF-κB inhibitor sodium salicylate is also capable of preventing the accumulation of ceramides in the hypothalamus with lipid infusion (58).

**Development.** Another intriguing possible link between inflammation and the risk for obesity involves events in early embryonic development. Epidemiologic and animal models have demonstrated a strong association between the prenatal and perinatal environment and obesity-associated diseases (69). The risk for obesity and metabolic disorders follows a U-shaped distribution based on birth weight, with increased risk in low- and high-birth-weight infants (70, 71). Since pregnancy represents a physiologic inflammatory state involving the innate and acquired immune system, inflammatory mechanisms may contribute to the in utero programming of nutrient metabolism (72). Maternal obesity is associated with endotoxemia and ATM accumulation that may affect the developing fetus (73). Placental inflammation is a characteristic of maternal obesity, a risk factor for obesity in offspring, and involves inflammatory macrophage infiltration that can alter the maternal-fetal circulation (74). Inflammatory disturbances in the placenta may alter the nutrient set points established early in life and predispose to an accelerated pattern of catch-up growth that contributes to the risk for later obesity, especially in low-birth-weight infants (75, 76). The concept that inflammatory networks can influence the predilection toward obesity is supported by the find-
ings that variation in obesity susceptibility between mouse strains is intrinsically linked to the inflammatory networks and leukocyte composition of adipose tissue established prior to HFD exposure (77). Overall, there is much to be learned about how maternal and paternal factors contribute to the epigenetic programming of metabolism genes that contribute to long-term effects on adult body weight (78, 79). It will be interesting to see whether inflammatory response genes are coordinately altered with metabolic genes important in maintaining proper nutrient metabolism. PKR, RNA-dependent protein kinase.

**How does inflammation cause metabolic dysfunction?**

Many molecular signaling pathways have been described at the interface between inflammation and metabolism (e.g., insulin receptor signaling in macrophages; ref. 80). Here we will highlight several prominent pathways that are coordinately regulated during obesity that translate a metabolic challenge into an inflammatory response and contribute to obesity-associated disease (Figure 2).

**PRRs as metabolic sensors.** PRRs are components of the innate immune system well known for their ability to sense foreign molecules (pathogen-associated molecular patterns) and initiate a defense response. However, the ability of PRRs to sense endogenous ligands induced in the obese state is now understood to be a trigger in obesity-associated inflammation. Of these PRRs, TLR4 has received the most attention, as this receptor can be activated by free FAs to generate proinflammatory signals and activate NF-κB (81). TLR4-deficient mice are protected from the inflammatory activation induced by obesity and demonstrate protection from insulin resistance induced by lipid infusion (82). Part of this effect is mediated by leukocytes (83), but there is clear evidence that direct effects of TLR4 activation in non-hematopoietic cells contribute to the metabolic phenotype (53). Adipose tissue expresses nearly all TLR family members, and TLR2-knockout mice are protected from high-fat DIO and insulin resistance, suggesting a broad role for TLRs in obesity and its associated morbidities (84, 85). Besides FAs, TLRs also sense and regulate gut microbes in a way that contributes to metabolism, as Tlr5−/− mice demonstrate obesity and insulin resistance related to alterations in the gut microbiome (86).

The Nod-like receptor (NLR) family of PRRs also sense obesity-induced signals in multiple contexts. NLRs are activated by danger signals from stressed or dying cells and mobilize leukocytes toward these stimuli to constrain tissue damage (87, 88). In macrophages, NLR activation stimulates the cryptopyrin/NLRP3 inflammasome to induce IL-1β and IL-18 production via caspase-1. These pathways contribute to pancreatic β cell death with chronic hyperglycemia and affect diabetes progression (89). Caspase-1 and IL-1β are also induced in adipose tissue with DIO, and Nlrp3- and Casp1-deficient mice demonstrate resistance to DIO-induced inflammation (90). The mechanism of this protective effect may be driven by alterations in the M1 activation of ATMs, as Nlrp3-knockout mice show decreased M1 and increased M2 gene expression without quantitative changes in ATMs. If PRRs can broadly act as dual sensors of pathogenic and endogenous signals relevant to obesity, the potential pathways contributing to metainflammation may be vast.

**IKKβ and NF-κB.** The intracellular signals downstream of TLR activation occur via multiple pathways, which may be dependent on, or independent of, the adaptor protein MyD88. While MyD88-dependent signaling contributes to hypothalamic inflammation with obesity (61), its role in other metabolic tissues is unclear, as Myd88−/− mice are more susceptible to insulin resistance with DIO (91). Activation of κB kinase-β (IKKβ) occurs downstream of MyD88 and plays critical roles in inflammation in the liver, myeloid cells, and the hypothalamus in the obese state (92, 93). This wide range of action likely explains the insulin-sensitizing effect of salicylate, an IKKβ inhibitor that is currently in clinical trials for type 2 diabetes therapy (94, 95).

The ultimate endpoint for TLR/IKKβ signals is NF-κB–dependent activation of inflammatory gene transcription (96). In vivo imaging of NF-κB activation identified adipose tissue and ATMs...
Ceramides and intracellular lipids in inflammation and metabolism.

The downstream effects of TLR4 activation are not limited to the activation of NF-κB. A key common denominator between metabolism and inflammation may lie in the balance between intracellular lipid species such as ceramides and sphingolipids (99, 100). Inhibition of ceramide production blocks the ability of saturated FAs to induce insulin resistance (101). The induction of ceramide synthesis by LPS and saturated FA is dependent upon saturated FAs to induce insulin resistance (101). The induction of TLR4 in many metabolic tissues, including the hypothalamus and muscle, where ceramide production can inhibit insulin signaling through Akt (58). TLR4-mediated ceramide production in metabolic tissues is dependent on IKKβ, as salicylates decrease ceramide levels in the liver, muscle, and hypothalamus.

The adipokine adiponectin has long been recognized to have positive effects on multiple cell types to promote insulin sensitivity and deactivate proinflammatory pathways. Ceramide regulation may be a common denominator of these effects, as adiponectin stimulates ceramidase activity and modulates the balance between ceramides and sphingosine-1-phosphate (102). The influence of adiponectin on ceramide content in cells appears to be important for multiple tissues, as it guards against apoptosis of cardiomyocytes and β-cells (102). Adiponectin receptor–associated ceramidase activity may not be the only mechanism at play. Awazawa et al. found that insulin sensitivity was improved with adiponectin infusion in hepatocytes via IRS2 induction; however, this was not cell autonomous (103). Surprisingly, induction of IL-6 by adiponectin in macrophages generated this insulin-sensitizing effect; this was largely independent of adiponectin receptors R1 and R2.

JNK and ER stress. In addition to NF-κB, obesity also activates JNK in insulin-responsive tissues, probably through upstream pathways shared by IKK/NF-κB in response to stress signals such as FAs, insulin, hyperglycemia, and inflammatory cytokines (104). The differential contribution of JNK in hematopoietic and nonhematopoietic cells in obesity is well described compared with other inflammatory signaling components. While both JNK1 and JNK2 isomers contribute to metabolic regulation, JNK1 has a more prominent role in the protection from DIO (105, 106). The effects of JNK1 in nonhematopoietic cells control body weight and energy expenditure. As with the IKKβ pathway, JNK1 also regulates hypothalamic signals; inactivation of JNK1 in the hypothalamus protects mice from DIO and recapitulates the reduced body weight phenotype seen in the whole body of JNK1-deficient animals (107). JNK1 inactivation in hematopoietic cells does not alter adiposity but is sufficient to attenuate obesity-induced inflammation with beneficial effects on metabolism (108, 109).

ER stress and the downstream activation of the molecular pathways governing the unfolded protein response appear to be closely tied to both JNK1 and IKK/NF-κB activation pathways in multiple metabolic tissues (e.g., hypothalamus and adipose tissue) (110). Widespread activation of ER stress signaling components and cascades (ATF6, PERK, IRE-1) is seen in obesity, and pharmacologic inhibition of ER stress can reverse metabolic dysfunction (43, 111). The double-stranded RNA-dependent protein kinase represents a PRR that sits at the interface between ER stress and nutrients to translate these signals into an inflammatory response through JNK (112). Further work is needed to establish how widespread ER stress is in other acute and chronic stress situations and how its mechanism overlaps with its role in the pathogenesis of atherosclerosis and foam cell biology (113).

Antiinflammatory therapies for metabolic disease

The observations above demonstrate potential new approaches toward the development of drugs that target inflammation to break the links between obesity and disease. Salsalate, a prodrug of salicylate, can attenuate IKKβ/NF-κB activity and has been shown to improve glycemic control in patients with type 2 diabetes (95, 114). Preclinical studies have also demonstrated a metabolic benefit related to the antiinflammatory effects of targeting ER stress (111) and PPARγ (115). Blockade of inflammatory cytokine signals in metabolic disease also shows promise, as IL-1 receptor antagonists (anakinra) improve glycemia and β-cell function and decrease systemic inflammatory markers (116). In aggregate, TNF-α blockade with etanercept has not demonstrated significant improvements in insulin sensitivity, but beneficial effects of TNF-α blockade on fasting glucose and circulating inflammatory cytokines have been observed, suggesting application in other obesity-related morbidities (117, 118).

Conclusion

The unexpected overlap between inflammatory and metabolic sensors and their downstream tissue responses indicates that inflammation plays a crucial role in the many complications of obesity. However, there remain many contradictions that have yet to be sorted out, such as how hypothalamic inflammation causes both obesity and anorexia, the role of the innate immune system in maintaining obesity, and the teleological reasons for obesity-dependent inflammation, among others. We feel that answering these questions requires approaches that allow a higher-resolution view of the different cellular mediators (e.g., macrophages, adipocytes, and lymphocytes) in fat that contribute to disease phenotypes. A second challenge will be to establish the differences and similarities between acute inflammatory signals and chronic activation of these pathways in diseases such as obesity. This temporal question is also a critical one for immunologists, who are employing systems biology approaches to tease out the dynamic network effects of transient versus persistent stimuli (119). These efforts provide opportunities to continue to revise our understanding of the nature of metaflammation in the hope of modifying it to prevent and treat disease.

Acknowledgments

The Obesity Review Series is supported in part by unrestricted educational grants from Merck & Co. and the Life Sciences Institute of the University of Michigan. This work was supported by NIH National Institute of Diabetes and Digestive and Kidney Diseases grants to C.N. Lumeng (R01DK090262, K08DK078851) and A.R. Saltiel (R01DK060591).

Address correspondence to: Carey Lumeng, University of Michigan Medical School, Department of Pediatrics and Communicable Diseases, 4520B MSRB I, 1150 W Medical Center Drive, Ann Arbor, Michigan 48109-5652, USA. Phone: 734.936.4200; Fax: 734.763.9512; E-mail: clumeng@umich.edu.


